Healthcare giant Johnson & Johnson (NYSE:JNJ) today announced a new collaborative deal as it looks to develop a vaccine against Middle East Respiratory Syndrome Coronavirus.
The collaborative deal is between J&J’s Janssen Vaccines & Prevention division, the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford, J&J said. Through the deal, Janssen will provide its expertise in tech and vaccine development, and will also work on novel vaccines against the Lassah and Nipah viruses.
Read the whole story on our sister site, Drug Delivery Business News
The post J&J inks collab deal to develop MERS vaccine appeared first on MassDevice.